FACT SHEET
Using Cells for Healing
About RepliCel
RepliCel Life Sciences is a regenerative medicine company
focused on developing autologous cell therapies that
address conditions linked to a deficit of healthy cells
required for normal healing and function.
Partnerships. Shiseido has an exclusive license for RCH-01
in certain Asian countries including Japan, China and South
Korea. The company is actively engaging potential partners
for its other products.
Products / Markets. The company’s RCT-01, RCS-01, and
RCH-01 cell therapies are designed to treat chronic
tendinosis, damaged or aged skin, and pattern baldness.
RepliCel is also developing a propriety, next-generation
injection device (RCI) for optimal clinical delivery. Each
condition is related to a deficit of a specific cell type which
we believe is critical to the restoration of normal function.
Strategy. Management initiated a clearly defined 18month value creation plan in Q1 2015. The Company is
launching multiple clinical trials anticipated to start in 2015
in addition to Shiseido’s own clinical trial of RCH-01,
finalizing prototype development and obtaining a CE mark
for the RCI injector device, initiating other clinical trials,
executing other licensing deals, multiple manufacturing
improvements, and specific research programs targeting
other products and applications.
Technology / IP. Innovative technology protected by both
patents (issued and filed) and trade secrets on the cell
isolation, product composition, manufacturing and clinical
applications.
The company is structured to minimize its own
infrastructure and leverage partners for commercialization.
Investment Highlights
1. Innovative products with significant best-in-class
commercial applications
2. Proprietary technologies to harvest, expand and reintroduce hair follicle derived cells
3. Three immanent clinical trial starts with 2016
readouts for tendon and skin
4. Strong IP covering process/use of the company’s
technology
5. One of the few global regenerative medicine
companies to have a Japanese partnership positioned
to leverage the opportunity for expedited market
approval now available through recent Japanese
regulatory reforms
6. Partnership with Shiseido, 4th largest cosmetics
company worldwide ($31 M plus royalties)
7. 2015 focus on geographic licensing for tendon, skin
and injector device
Pipeline of Products
RepliCel’s product pipeline leverages the unique
cellular properties of the hair follicle to develop
a portfolio of products that treat functional
cellular deficits as a result of injury, normal
aging or genetic predisposition.
Shiseido Clinical Trial in Japan
Shiseido has built a cell-processing facility to
handle all aspects of their RCH-01 clinical trial to
be conducted in Japan. All product and clinical
development, as well as data, will be shared
with the goal of commercializing a safe and
effective treatment for pattern baldness.
This Fact Sheet is provided by RepliCel Life Sciences Inc. as a convenience for potential investors. More details about the business and its risks can be
found in the company’s press releases and filings with the U.S. Securities and Exchange Commission or the Canadian Securities Administrators. This Fact
Sheet may contain forward-looking statements and actual results may differ materially from such statements.
RCT-01: NBDS Fibroblast Therapy
Treatment for Chronic Tendinosis
•
•
•
•
Uses non-bulbar dermal sheath (NBDS) cells derived from the hair follicle
NBDS cells are prolific producers of type I collagen (5x dermal fibroblasts)
These cells and the collagen they produce play an important role in tendon healing
Phase 1/2 in chronic Achilles tendinosis: 2015 (Cleared by Health Canada Nov. 2014)
RSC-01: NBDS Fibroblast Therapy
Treatment for Aging & Sun Damaged Skin
• Uses non-bulbar dermal sheath (NBDS) cells derived from the hair follicle
• NBDS cells are prolific producers of type I collagen (5x dermal fibroblasts)
• These cells and the collagen they produce play an important role in reversing
skin aging and damage
• Phase 1 in aging and sun damaged skin: 2015
RCH-01: DSC Cell Therapy
Treatment for Androgenetic Alopecia
• Utilizes dermal sheath cup (DSC) cells derived from the hair follicle
• DSC cells regulate the volume of dermal papillae (DP) cells which are
responsible for thickness and growth of hair fibers
• Phase 2 in pattern baldness: 2015-6
RCI-02 Dermatology Injector Device
Dermal Applications
•
•
•
•
Programmable depth and volume with improved control and precision
Cooling plate replaces need for local anesthetic
Interchangeable heads for different applications
Prototype build stage
How it Works
For all products, specific cells are isolated from a small biopsy taken from
the back of a patient’s scalp. Specific cells are isolated and replicated per
proprietary manufacturing processes, stored in cryogenic vials for
shipment to the clinic and thawed for re-injection into the area of the
patient’s cellular deficit.
Market Data
April 30/15
Exchange:
OTCQB/TSXV
Management Team
52 Wk H/L CAD:
David Hall, BSc – CEO, President & Director
Lee Buckler, LLB - VP Business & Corporate Development
Rolf Hoffmann, MD - CMO & Director
Kevin McElwee, PhD - Chief Scientific Officer
Tom Kordyback, CA - Chief Financial Officer
Darrell Panich, MSc CPM - VP Clinical Affairs
Hisae Nakamura, PhD - Director, R&D
Symbol:
REPCF / RP
Issued and Out:
54,947,288
Fully Diluted:
67,807,343
Market Cap:
$0.30-$0.80
$24 M
R. Lee Buckler
VP Business & Corporate Development
604.248.8693
[email protected] / www.replicel.com